MUSC Receives Approval for Large-Scale Clinical Trial of New Respiratory Drug

Greenville Spartanburg Asheville Anderson, SC, August 19, 2026 —

CHARLESTON, SC – The Medical University of South Carolina (MUSC) has been granted approval to commence a significant clinical trial involving 3,000 participants for a new drug named Nebtula. This medication is being developed to address severe respiratory symptoms associated with illnesses such as COVID-19, influenza, and Respiratory Syncytial Virus (RSV).

The initiative is supported by $27.7 million in state pandemic aid, marking a crucial phase in the drug’s journey toward potential Food and Drug Administration (FDA) approval. This trial is designed as the final step in the regulatory process.

Beyond seeking regulatory approval for Nebtula, the trial also has a broader objective: to establish South Carolina as a center for pharmaceutical research and manufacturing. This endeavor aims to leverage the state’s resources and expertise in the burgeoning field of biopharmaceutical development.

Participants in the trial will undergo monitoring through a combination of telemedicine and wearable devices. This approach is intended to facilitate comprehensive data collection while offering convenience to participants. The projected duration for the completion of this extensive trial is four years.

The development and testing of new treatments for respiratory illnesses remain a priority, particularly in the wake of recent global health challenges. The success of this trial could represent a significant advancement in managing the severe symptoms of these common and potentially dangerous diseases.

Story summarized from the original created by Jessica Holdman on scdailygazette.com, see more information here.

Media gallery